Latest lactulose Stories

NASHVILLE, Tenn., April 25, 2013 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) announced today that it will release its first quarter 2013 results after the market closes on Thursday, May 2, 2013. A conference call and live Internet webcast will be held on Thursday, May 2, 2013, at 4:30 p.m. Eastern Time to discuss the results. To participate in the call, please dial 877-303-1298 (for U.S. callers) or 253-237-1032 (for international callers). A rebroadcast of the...

NASHVILLE, Tenn., Feb. 14, 2013 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release 2012 year-end financial results after the market closes on Thursday, February 28, 2013. A conference call and live Internet webcast will be held on Thursday, February 28, 2013, at 4:30 p.m. Eastern Time to discuss the results. To participate in the call, please dial 877-303-1298 (for U.S. callers) or 253-237-1032 (for international callers). A...

NASHVILLE, Tenn., Oct. 18, 2012 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) announced today that it will release third quarter 2012 results after the market closes on Thursday, November 1, 2012. A conference call and live Internet webcast will be held on Thursday, November 1, at 4:30 p.m. Eastern Time to discuss the results. To participate in the call, please dial 877-303-1298 (for U.S. callers) or 253-237-1032 (for international callers). A rebroadcast of the...

Inhibitory control test and lactulose saves more than $3 million over 5 years A late stage liver condition, known as minimal hepatic encephalopathy (MHE), is associated with impaired driving skills and greater risk of motor vehicle accidents. Cost analysis of management strategies for detection and treatment of MHE are published in the April issue of Hepatology, a journal of the American Association for the Study of Liver Diseases. Findings report that MHE diagnosis using the inhibitory...

NASHVILLE, Tenn., Dec. 1, 2010 /PRNewswire-FirstCall/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) today announced the publication of a patient preference study evaluating Kristalose®( )(lactulose) for Oral Solution, a prescription laxative packaged as a crystalline powder, compared to liquid lactulose products. The study, which appeared in the Volume 3, 2010 issue of Clinical and Experimental Gastroenterology, showed that patients with chronic constipation preferred the taste,...

NASHVILLE, Tenn., May 13 /PRNewswire-FirstCall/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on the hospital acute care and gastroenterology markets, today announced first quarter 2010 financial results. "We remain focused on gaining widespread hospital formulary approval for Caldolor and our efforts are producing meaningful results," said A.J. Kazimi, Chief Executive Officer of Cumberland Pharmaceuticals. "We will continue to extend our...

NASHVILLE, Tenn., April 26 /PRNewswire-FirstCall/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) today announced that results from a patient preference study evaluating Kristalose® (lactulose) for Oral Solution, a prescription laxative packaged as a crystalline powder, will be presented at the 2010 Digestive Disease Week® meeting in New Orleans. A poster presentation of the study, entitled "An open-label, multi-center, randomized, 7-day crossover study of the preference and...

NASHVILLE, Tenn., Dec. 15 /PRNewswire-FirstCall/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) today announced new top-line results for a patient preference study evaluating Kristalose (lactulose) for Oral Solution, a prescription laxative packaged as a crystalline powder, compared to similar products in liquid forms. Kristalose is the only prescription-strength laxative available in pre-measured powder packets. Over a 14-day period, 50 patients with a recent diagnosis of chronic...

The Company also Initiates the Phase 2b ASTUTE Clinical Trial for Mild Hepatic Encephalopathy SAN DIEGO, April 28 /PRNewswire/ -- Ocera Therapeutics, Inc., a privately held biopharmaceutical company, announced that data from its phase 2 study of AST-120 for the treatment of patients with low-grade hepatic encephalopathy was presented April 25th at the 44th Annual Meeting of the European Association for the Study of Liver Disease (EASL) in Copenhagen. The study showed that AST-120 was...

By Lydia Gehring The topic was unlikely for a small group of professional women. We were enjoying a much-needed lunch break during a dietetic conference. The youngest in the group was a new mother. Her toddler was constipated and we were brainstorming. The small boy had not pooped in four days and the mom was frantic. She had her hand on top of her cell phone and was eagerly awaiting a call from the daycare worker. The little guy was teething and beginning to walk. Her mother-in- law was...